Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

Video

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

Jesus G. Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

The median administered dose of JNJ-4528 in the ​phase 1b/2 CARTITUDE-1 trial was 0.72 x 106 CAR + viable T cells/kg,which is lower than other available CAR T-cell products, says Berdeja.

With this dosing strategy, a 70 kg patient would receive about 50 million CAR T cells, explains Berdeja. Although additional information is needed, making fewer CAR T cells may lead to less manufacturing failures.

Moreover, data from the ​CARTITUDE-1 trial showed that the ​median time to onset of cytokine release syndrome (CRS) was 7 days after receiving JNJ-4528. Comparatively, CRS can be observed immediately after infusion with other ​CAR T-cell products, Berdeja concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,